Interaction Checker

Interaksi Alosetron

Alosetron (Lotronex) memiliki 88 interaksi terdokumentasi dalam label FDA dan lembar fakta yang kami indeks: 11 mayor, 42 moderat, 3 minor, dan 32 dengan label yang melaporkan tidak ada interaksi bermakna. Setiap entri di bawah ini mengutip kalimat yang mendasarinya. Halaman obat ini adalah titik awal, bukan putusan untuk situasi Anda.

Seperti apa tampilan Alosetron

Semua 6 versi
Tablet Alosetron 1 mg: biru, oval, 11 mm, dengan kode cetak GX di satu sisi dan CT1 di sisi lainnya.
GX / CT1
1 mg · biru · oval · 11 mm
Sebela
Tablet Alosetron 0.5 mg: putih, oval, 11 mm, dengan kode cetak GX di satu sisi dan EX1 di sisi lainnya.
GX / EX1
0.5 mg · putih · oval · 11 mm
Sebela
Tablet Alosetron 0.5 mg: putih, oval, 11 mm, dengan kode cetak AN248.
AN248
0.5 mg · putih · oval · 11 mm
Amneal
Tablet Alosetron 1 mg: biru, oval, 11 mm, dengan kode cetak AN249.
AN249
1 mg · biru · oval · 11 mm
Amneal

Gambar hasil render dari daftar produk pada label FDA: warna, bentuk, ukuran, dan kode cetak. 6 versi terdokumentasi dari 6 pelabel.

Interaksi dari label

Interaksi mayor (11)

  • Deferasirokssuplemen zat besiMayor

    Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold [see Drug Interactions ( 7.1 )] . (label Alosetron, Kontraindikasi)

  • FluvoksaminSSRIMayor

    Concomitant use of fluvoxamine ( 4.3 ) (label Alosetron, Kontraindikasi)

  • Kanabidiol (obat resep)antikonvulsanMayor

    Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold [see Drug Interactions ( 7.1 )] . (label Alosetron, Kontraindikasi)

  • LevofloksasinfluorokuinolonMayor

    Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions. (label Alosetron, Interaksi obat)

  • MeksiletinantiaritmiaMayor

    Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold [see Drug Interactions ( 7.1 )] . (label Alosetron, Kontraindikasi)

  • MoksifloksasinfluorokuinolonMayor

    Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions. (label Alosetron, Interaksi obat)

  • OfloksasinfluorokuinolonMayor

    Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions. (label Alosetron, Interaksi obat)

  • Simetidinpenghambat H2Mayor

    Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold [see Drug Interactions ( 7.1 )] . (label Alosetron, Kontraindikasi)

  • SiprofloksasinfluorokuinolonMayor

    Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold [see Drug Interactions ( 7.1 )] . (label Alosetron, Kontraindikasi)

  • Viloksazinpenghambat ambilan kembali norepinefrinMayor

    Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold [see Drug Interactions ( 7.1 )] . (label Alosetron, Kontraindikasi)

  • Zileutonpenghambat CYP1A2Mayor

    Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold [see Drug Interactions ( 7.1 )] . (label Alosetron, Kontraindikasi)

Interaksi moderat (42)

  • AmiodaronantiaritmiaModerat

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (label Alosetron, Interaksi obat)

  • Aprepitantpenghambat CYP3A4Moderat

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (label Alosetron, Interaksi obat)

  • AtazanavirantiretroviralModerat

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (label Alosetron, Interaksi obat)

  • DarunavirantiretroviralModerat

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (label Alosetron, Interaksi obat)

  • Darunavir dan kobisistatantiretroviralModerat

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (label Alosetron, Interaksi obat)

  • Diltiazempenghambat kanal kalsiumModerat

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (label Alosetron, Interaksi obat)

  • DronedaronantiaritmiaModerat

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (label Alosetron, Interaksi obat)

  • EfavirenzantiretroviralModerat

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (label Alosetron, Interaksi obat)

  • Efavirenz, lamivudin, dan tenofovirantiretroviralModerat

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (label Alosetron, Interaksi obat)

  • EluksadolinopioidModerat

    Examples: alosetron, anticholinergics, opioids Table 3: Established and Other Potentially Clinically Relevant Interactions Affecting Drugs Co-Administered with VIBERZI OATP1B1 and BCRP Substrate Clinical Impact: VIBERZI may increase the exposure of co-administered OATP1B1 and BCRP substrates. (label Eluksadolin, Interaksi obat)

  • Elvitegravir, kobisistat, emtrisitabin, dan tenofovirantiretroviralModerat

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (label Alosetron, Interaksi obat)

  • Eritromisinantibiotik makrolidaModerat

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (label Alosetron, Interaksi obat)

  • EverolimusimunosupresanModerat

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (label Alosetron, Interaksi obat)

  • Flukonazolantijamur azolModerat

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (label Alosetron, Interaksi obat)

  • FosamprenavirantiretroviralModerat

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (label Alosetron, Interaksi obat)

  • Fosaprepitantpenghambat CYP3A4Moderat

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (label Alosetron, Interaksi obat)

  • Imatinibpenghambat CYP3A4Moderat

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (label Alosetron, Interaksi obat)

  • IsoniazidantibiotikModerat

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (label Alosetron, Interaksi obat)

  • Itrakonazolantijamur azolModerat

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (label Alosetron, Interaksi obat)

  • Ivakaftorpenghambat CYP3A4Moderat

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (label Alosetron, Interaksi obat)

  • Ketokonazolantijamur azolModerat

    Ketoconazole increased mean alosetron plasma concentrations (AUC) by 29%. (label Alosetron, Interaksi obat)

  • Klaritromisinantibiotik makrolidaModerat

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (label Alosetron, Interaksi obat)

  • LeflunomidimunosupresanModerat

    In patients taking ARAVA, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced. (label Leflunomid, Interaksi obat)

  • LenakapavirantiretroviralModerat

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (label Alosetron, Interaksi obat)

  • Lopinavir dan ritonavirantiretroviralModerat

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (label Alosetron, Interaksi obat)

  • Mifepristonpenghambat CYP3A4Moderat

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (label Alosetron, Interaksi obat)

  • Mirabegronagonis beta-adrenergikModerat

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (label Alosetron, Interaksi obat)

  • NefazodonantidepresanModerat

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (label Alosetron, Interaksi obat)

  • Nirmatrelvir dan ritonavirantivirusModerat

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (label Alosetron, Interaksi obat)

  • Palbosiklibpenghambat CYP3A4Moderat

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (label Alosetron, Interaksi obat)

  • PerampanelantikonvulsanModerat

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (label Alosetron, Interaksi obat)

  • Posakonazolantijamur azolModerat

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (label Alosetron, Interaksi obat)

  • PrimakuinantimalariaModerat

    Effects of Primaquine on the Pharmacokinetics of Other Drugs CYP1A2 Substrates Published clinical and non-clinical reports indicate primaquine inhibits CYP1A2 enzyme activity and thus may lead to increased exposure of CYP1A2 substrate drugs (e.g., duloxetine, alosetron, theophylline and tizanidine) when co-administered with Primaquine phosphate Tablets. (label Primakuin, Interaksi obat)

  • Ranolazinobat yang memperpanjang interval QTModerat

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (label Alosetron, Interaksi obat)

  • RitonavirantiretroviralModerat

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (label Alosetron, Interaksi obat)

  • SenobamatantikonvulsanModerat

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (label Alosetron, Interaksi obat)

  • SiklosporinimunosupresanModerat

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (label Alosetron, Interaksi obat)

  • Suvoreksantsedatif-hipnotikModerat

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (label Alosetron, Interaksi obat)

  • TeriflunomidimunosupresanModerat

    In patients taking AUBAGIO, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced. (label Teriflunomid, Interaksi obat)

  • TikagrelorantiplateletModerat

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (label Alosetron, Interaksi obat)

  • Verapamilpenghambat kanal kalsiumModerat

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (label Alosetron, Interaksi obat)

  • Vorikonazolantijamur azolModerat

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (label Alosetron, Interaksi obat)

Penyebutan minor (3)

  • HidralazinvasodilatorMinor

    Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine. (label Alosetron, Interaksi obat)

  • Isosorbid dinitrat dan hidralazinnitratMinor

    Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine. (label Alosetron, Interaksi obat)

  • ProkainamidantiaritmiaMinor

    Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine. (label Alosetron, Interaksi obat)

Tidak ada interaksi bermakna yang dilaporkan (32)

  • Alopurinolpenghambat xantin oksidaseTanpa interaksi

    The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (label Alosetron, Interaksi obat)

  • AminofilinmetilxantinTanpa interaksi

    The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (label Alosetron, Interaksi obat)

  • Butalbital, aspirin, dan kafeinbarbituratTanpa interaksi

    The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (label Alosetron, Interaksi obat)

  • Butalbital, aspirin, kafein, dan kodeinbarbituratTanpa interaksi

    The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (label Alosetron, Interaksi obat)

  • Butalbital, parasetamol, dan kafeinbarbituratTanpa interaksi

    The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (label Alosetron, Interaksi obat)

  • Butalbital, parasetamol, kafein, dan kodeinbarbituratTanpa interaksi

    The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (label Alosetron, Interaksi obat)

  • Desogestrel dan etinilestradiolkontrasepsi oralTanpa interaksi

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (label Alosetron, Interaksi obat)

  • Drospirenon dan etinilestradiolkontrasepsi oralTanpa interaksi

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (label Alosetron, Interaksi obat)

  • Ergotamin dan kafeinalkaloid ergotTanpa interaksi

    The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (label Alosetron, Interaksi obat)

  • EstradiolestrogenTanpa interaksi

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (label Alosetron, Interaksi obat)

  • Estradiol dan dienogestkontrasepsi oralTanpa interaksi

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (label Alosetron, Interaksi obat)

  • Estradiol dan noretisteronestrogenTanpa interaksi

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (label Alosetron, Interaksi obat)

  • Estrogen teresterifikasi dan metiltestosteronestrogenTanpa interaksi

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (label Alosetron, Interaksi obat)

  • Estrogen terkonjugasiestrogenTanpa interaksi

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (label Alosetron, Interaksi obat)

  • Estrogen terkonjugasi dan bazedoksifenestrogenTanpa interaksi

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (label Alosetron, Interaksi obat)

  • Etinodiol diasetat dan etinilestradiolkontrasepsi oralTanpa interaksi

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (label Alosetron, Interaksi obat)

  • Etonogestrel dan etinilestradiolestrogenTanpa interaksi

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (label Alosetron, Interaksi obat)

  • Febuksostatpenghambat xantin oksidaseTanpa interaksi

    The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (label Alosetron, Interaksi obat)

  • FulvestrantestrogenTanpa interaksi

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (label Alosetron, Interaksi obat)

  • LevonorgestrelprogestinTanpa interaksi

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (label Alosetron, Interaksi obat)

  • Levonorgestrel dan etinilestradiolkontrasepsi oralTanpa interaksi

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (label Alosetron, Interaksi obat)

  • MedroksiprogesteronprogestinTanpa interaksi

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (label Alosetron, Interaksi obat)

  • MegestrolprogestinTanpa interaksi

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (label Alosetron, Interaksi obat)

  • Norelgestromin dan etinilestradiolestrogenTanpa interaksi

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (label Alosetron, Interaksi obat)

  • NoretisteronprogestinTanpa interaksi

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (label Alosetron, Interaksi obat)

  • Noretisteron dan etinilestradiolkontrasepsi oralTanpa interaksi

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (label Alosetron, Interaksi obat)

  • Norgestimat dan etinilestradiolkontrasepsi oralTanpa interaksi

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (label Alosetron, Interaksi obat)

  • Norgestrel dan etinilestradiolkontrasepsi oralTanpa interaksi

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (label Alosetron, Interaksi obat)

  • Orfenadrin, aspirin, dan kafeinpelemas ototTanpa interaksi

    The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (label Alosetron, Interaksi obat)

  • PentoksifilinmetilxantinTanpa interaksi

    The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (label Alosetron, Interaksi obat)

  • ProgesteronprogestinTanpa interaksi

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (label Alosetron, Interaksi obat)

  • TeofilinmetilxantinTanpa interaksi

    The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (label Alosetron, Interaksi obat)

Periksa Alosetron terhadap semua yang Anda gunakan. Tambahkan seluruh daftar Anda; setiap pasangan diperiksa sekaligus.

Buka di pemeriksa

Bukan nasihat medis. Tingkat keparahan mencerminkan kata-kata dalam label, bukan keadaan Anda. Tanda “mayor” bisa merupakan hal yang rutin di bawah pengawasan, dan tanda “minor” bisa menjadi penting pada dosis tinggi. Tanyakan kepada apoteker.